Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $63.7 million.

  • Karyopharm Therapeutics' Cash & Current Investments fell 5589.69% to $63.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $63.7 million, marking a year-over-year decrease of 5589.69%. This contributed to the annual value of $63.7 million for FY2025, which is 5589.69% down from last year.
  • According to the latest figures from Q4 2025, Karyopharm Therapeutics' Cash & Current Investments is $63.7 million, which was down 5589.69% from $45.9 million recorded in Q3 2025.
  • Karyopharm Therapeutics' Cash & Current Investments' 5-year high stood at $278.0 million during Q4 2022, with a 5-year trough of $45.9 million in Q3 2025.
  • For the 5-year period, Karyopharm Therapeutics' Cash & Current Investments averaged around $170.9 million, with its median value being $181.1 million (2022).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 4039.2% in 2023, then plummeted by 6601.65% in 2025.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Cash & Current Investments stood at $228.6 million in 2021, then rose by 21.59% to $278.0 million in 2022, then tumbled by 31.13% to $191.4 million in 2023, then decreased by 24.5% to $144.5 million in 2024, then crashed by 55.9% to $63.7 million in 2025.
  • Its Cash & Current Investments was $63.7 million in Q4 2025, compared to $45.9 million in Q3 2025 and $51.7 million in Q2 2025.